| Literature DB >> 20137931 |
Marvin J Meyers1, Matthew Pelc, Satwik Kamtekar, Jacqueline Day, Gennadiy I Poda, Molly K Hall, Marshall L Michener, Beverly A Reitz, Karl J Mathis, Betsy S Pierce, Mihir D Parikh, Deborah A Mischke, Scott A Long, John J Parlow, David R Anderson, Atli Thorarensen.
Abstract
The work described herein demonstrates the utility of structure-based drug design (SBDD) in shifting the binding mode of an HTS hit from a DFG-in to a DFG-out binding mode resulting in a class of novel potent CSF-1R kinase inhibitors suitable for lead development. Copyright 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20137931 DOI： 10.1016/j.bmcl.2010.01.078
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823